Viridian Therapeutics develops engineered antibody biologics that target IGF‑1R and FcRn to treat thyroid eye disease and other rare autoimmune disorders. Its pipeline offers high‑specificity antibodies with both intravenous and subcutaneous delivery, aiming for improved safety, tolerability, and patient convenience.
Funding
$251.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with rare autoimmune diseases such as thyroid eye disease have limited therapeutic options that often provide suboptimal efficacy, safety, or convenience, leading to unmet medical needs and reduced quality of life.
Solution
Viridian Therapeutics applies its expertise in antibody discovery and engineering to create optimized biologic medicines targeting well‑validated pathways implicated in autoimmune and rare diseases. The company’s pipeline includes anti‑IGF‑1R antibodies (Veligrotug, Elegrobart) for thyroid eye disease and anti‑FcRn antibodies (VRDN‑006, VRDN‑008) for broader autoimmune indications. By focusing on differentiated clinical activity, improved safety profiles, and convenient delivery routes (intravenous and subcutaneous), Viridian aims to advance candidates through clinical development faster than standard approaches. Ongoing pivotal Phase 3 trials and regulatory submissions demonstrate progress toward delivering new treatment options that can be administered more easily and tolerated better than existing therapies.
Target Audience
Primary customers are pharmaceutical partners, clinicians, and patients seeking advanced biologic therapies for thyroid eye disease and other rare autoimmune conditions.
Features
- Antibody platforms engineered for high specificity to disease‑relevant targets such as IGF‑1R and FcRn
- Dual administration routes (intravenous and subcutaneous) to enhance patient convenience
- Clinical programs spanning preclinical to Phase 3, including a BLA under priority review for Veligrotug
- Proprietary engineering to improve safety and tolerability compared with current standard‑of‑care biologics
- Focused pipeline addressing both a defined indication (thyroid eye disease) and broader autoimmune disorders